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Ihohaavan paraneminen alkaa re-epitelisaatiolla keratinosyyttien vaeltaessa haavan reunoilta kohti 
toisiaan. Solumigraatio alkaa jo ennen verisuonten uudismuodostusta, jolloin haavassa vallitsee 
hypoksiset olosuhteet. Syöpäsoluja tutkittaessa on havaittu, että hypoksia ja hapan ympäristö 
stimuloivat solumigraatiota. Hiilihappoanhydraasit (CA) ovat entsyymejä, jotka osallistuvat happo-
emästasapainon säätelyyn katalysoimalla hiilidioksidin reversiibeliä hydrataatiota bikarbonaatti-
ioniksi ja protoniksi. 
Tutkimuksessa selvitimme hiilihappoanhydraasien roolia ihohaavan paranemisessa. Havaitsimme, 
että CA IX sekä erityisesti CA IV ekspressoituivat ihohaavassa voimakkaasti 2-5 vuorokauden 
kohdalla, mikä antoi vahvoja viitteitä ko. entsyymien osallisuudesta haavan luonnolliseen 
paranemisprosessiin hypoksisen vaiheen aikana. Jatkotutkimuksessa selvitimme nopeuttaako CA IV 
ihohaavan paranemista hiirillä ja toisaalta hidastaako endogeenisen CA IV:n eliminointi sitä. 
Tutkittavia aineita lisättiin suoraan haavoihin ja haavat kerättiin viiden vuorokauden kuluttua. 
Paranemista arvioitiin määrittämällä histologisista näytteistä re-epitelisaation ja 
granulaatiokudosmuodostuksen aste sekä makroskooppisesti haavan koon perusteella. 
Re-epitelisaatiossa havaittiin tilastollisesti merkitsevä ero ryhmien välillä: CA IV:llä hoidetuilla 
hiirillä ihohaava sulkeutui nopeammin sekä inhibiittori- että kontrolliryhmään nähden. Sen sijaan 
inhibiittoriryhmässä oletettua haavan paranemisen hidastumista ei havaittu. 
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1. ABSTRACT 
 
Skin wound closure occurs when keratinocytes migrate from the edge of the wound and re-
epithelialize the epidermis. Their migration takes place primarily before any vascularization is 
established, i.e. under hypoxia, but relatively little is known about the factors that stimulate it. 
Hypoxia and acidic environment are well-established stimuli for cancer cell migration. The 
carbonic anhydrases (CAs) contribute to tumor cell migration by generating acidic environment 
through conversion of carbon dioxide to bicarbonate and a proton. We explored the possible role of 
CAs in wound healing using mouse models of skin wound healing. We show that the expression of 
CA IV and IX mRNAs are increased during the wound hypoxic period (days 2-5) and the cells 
expressing CAs form a band-like structure underneath migrating epidermis. RNA Seq analysis 
suggested that the CA IV-specific signal in the wound is mainly derived from neutrophils. Due to 
the high induction of CA IV, we treated skin wounds locally with recombinant human CA IV 
enzyme. Recombinant CA IV accelerated wound re-epithelialization during the hypoxic phase. 
Thus, CA IV could contribute to wound healing by providing acidic environment for the migrating 
epidermis and may offer novel opportunities to accelerate wound healing in compromised 
conditions.  
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2. INTRODUCTION 
 
The healing of a human skin wound is a complex and highly coordinated biological process 
involving diverse phenomena, such as hemostasis, inflammation, re-epithelialization, angiogenesis, 
fibroplasia, and finally tissue remodelling (Martin and Nunan, 2015; Woodley et al., 2015). “Re-
epithelialization” is the lateral migration of keratinocytes across the wound bed which, when 
successful, closes the wound (Martin and Nunan, 2015; Woodley et al., 2015). 
Re-epithelialization begins within hours after injury. It is believed that a critical switch for the 
initiation of cell migration by keratinocytes is the acute change in oxygen tension (Woodley et al., 
2015). That is, when the skin is wounded and the dermal blood vessels are clotted and no longer 
able to deliver oxygen to the skin, the keratinocytes experience the stress of acute hypoxia, and start 
migration to close the defect. Remarkably, the re-epithelialization takes place mainly in hypoxia 
and the wound closure can be completed before any new re-vascularization takes place (Woodley et 
al., 2015).  
Studies have shown that in addition to hypoxia, acidosis stimulates cancer cell migration (Benej et 
al., 2014; Pastorekova et al., 1997). Carbonic anhydrases (CA) are a family of zinc metalloenzymes 
that regulate the tissue acid-base equilibrium by catalysing the reversible hydration of carbon 
dioxide to bicarbonate ions and protons (CO2 + H2O <-> HCO3
- + H+) (Benej et al., 2014; 
Pastorekova et al., 1997; Waheed and Sly, 2014). 15 human CA isoforms have been found of which 
12 are active and 3 inactive (Aspatwar et al., 2013; Hilvo et al., 2008). These isoenzymes are 
expressed to some extent in all tissues and organs, but particularly in those that are metabolically 
highly active such as the brain and kidney (Benej et al., 2014; Waheed and Sly, 2014). Interestingly, 
expression of CAs IX and XII are induced by hypoxia in different tumors (Ivanov et al., 2001). 
Through their ability to regulate pH and generate acidic environment, these enzymes endow tumor 
cells with survival advantages in hypoxia/acidosis and confer an increased ability to migrate. 
The potency of CAs IX and XII to stimulate cell migration under hypoxia, prompted us to 
investigate the role of CAs in the skin wound healing. Quite unexpectedly, nothing is known about 
CAs during skin wound healing. We assumed that the expression of certain CA family members 
could increase when a wound is exposed to hypoxia and theoretically they could stimulate re-
epithelialization by generating acidic environment for keratinocytes. Thus, we studied the 
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expression pattern of the enzymatically active CAs in wounds of mice, and based on those results 
also treated the wounds with exogenously added CA IV recombinant enzyme. 
 
 
3. RESULTS 
 
3.1 The expression of CA IV and CA IX are induced during the hypoxic phase of 
wound healing  
To investigate the role of CAs in the skin wound healing process, we determined the expression 
pattern of 11 active members of the CA family (CA I, II, III, IV, Vb, VI, VII, IX, XII, XIII and XV) 
by qPCR analysis of wounds at different stages of healing , and compared their expression to the 
levels seen in normal, unwounded skin. Hypoxia persists in our excision wound model for five days 
after wounding, after which extensive angiogenesis vascularizes the wound bed and the wound is 
supplied with oxygen (Järvinen and Ruoslahti, 2007). Among the CA family members, the 
expression of CA IV mRNA was induced most strongly at almost 25-fold above normal two days 
after the wounding and remained elevated to more than 5-fold at five days after the wounding 
(Figure 1). CA IX was the only other enzyme that showed elevated expression during wound 
healing; its expression peaked at three days to a level more than 4-fold that of normal skin and the 
expression remained elevated at day 5 of the healing (Figure 1). After the skin wound is 
vascularized (from day 5 on), none of the CAs showed any enhanced expression at the mRNA level 
(Figure 1).  
As CAs IV and IX showed increased mRNA expression during the hypoxic phase of the wound 
healing, we decided to explore their expression in greater detail by immunohistochemistry. CA IV 
protein expression started to accumulate in the early granulation tissue at day 5 of the healing and 
positive expression remained in the wound until day 10, after which the expression disappeared 
(Figure 2). CA IV protein was expressed mainly by the cells in granulation tissue with especially 
strong, band-like, expression just beneath migrating epidermis (Figure 2). CA IX protein 
expression, in turn, was already seen in the skin wound at day 2 and remained elevated throughout 
the wound healing process, i.e. after CA IV had disappeared from the wound tissue (Figure 2). Both 
the epidermis and underlying granulation tissue expressed CA IX, but the strongest CA IX protein 
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expression was also seen in the migrating epidermis and just beneath the migrating epidermis in the 
top layer of dermis (Figure 2).  
 
3.2 CA transcripts in wound-related cells 
To elucidate the cell sources that produce CAs during wound healing, a thorough analysis of human 
RNA-Seq data was performed. RNA-Seq analysis of 12 cell types revealed that a CA4 transcript is 
expressed significantly only in skin and neutrophils (Figure 3). In both tissues only the 312 amino 
acid ENST00000300900 CA4 transcript is expressed. In the skin a total of 12 CA genes are 
expressed (Supplementary Table 2). Of these, CA4 has one of the lowest levels of expression with a 
normalized FPKM value of 160.18. In neutrophils the CA4 expression level is significantly higher 
than in skin with a FPKM of 7162.48.  CA9 expression was significant in fibroblasts, skin, and 
macrophages (Figure 3), with expression in fibroblasts significantly higher than the others. 
 
3.3 Characterization of CA4 promoter 
The unexpected and high level induction of CA4 mRNA in the skin wound prompted us to 
characterize the CA4 promoter in detail to provide clues on the potential regulation of its 
transcription. Our comparative genomics analysis of the aligned CA4 promoter regions of 15 
mammal species revealed a distinct cluster of high scoring and well conserved potential 
transcription factor binding sites immediately upstream of a similarly predicted TATA-binding 
protein binding site (Figure 4). Present in all 15 species is a strong signal for a CTCF binding site 
located from -55 to -44 bp upstream of the TSS (Figure 4). In 13 of the species, including human, 
this region is an exact match for previously experimentally determined CTCF binding sites. 
Overlapping the probable CTCF site are predicted binding sites for SP1, KLF4, and MZF1. The 
SP1 and MZF1 sites are a match for previously experimentally determined sites in all 15 species, 
while the KLF4 is a match in 14 species. The locations of binding are: -55 to -44 on the sense-
strand (CTCF), -50 to -39 on the anti-sense strand (SP1), -47 to -41 on the sense-strand (MZF1), 
and -49 to -39 on the sense-strand (KLF4) (Figure 4). Importantly, our results did not reveal any 
HIF-1αbinding sites in the CA4 promoter. 
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3.4 GO analysis of biological processes associated with CA4 in skin 
Next we wanted to understand the potential function of CA4 in skin wound healing and thus, 
performed gene ontology enrichment (GO) analysis of biological processed associated with CA4 
expression. GO enrichment analysis of genes with a strong expression correlation (≥0.50) with CA4 
in skin resulted in a total of 40 terms which were represented two-fold or higher in our set versus 
what was expected (Supplementary Table 3). The terms which had the highest over-representation 
in our set were strongly related to immune cell recruitment. Additionally, terms related to 
angiogenesis, endocytosis, inflammation, and ion homeostasis were also over-represented. 
 
3.5 Expression of Car4 is not induced by hypoxia in pure hypoxia-driven 
angiogenesis-model 
To explore whether hypoxia induced the expression of Car4 during wound healing, we next 
employed a pure hypoxia-driven angiogenesis of oxygen-induced retinopathy model (OIR).  We 
could not detect any induction of Car4 mRNA either by the hypoxia at P12 or by revascularization 
at P17 ruling out the possibility that CA4 is a hypoxia inducible gene (Supplementary Figure 1). 
 
3.6 Expression and characterization of recombinant CA IV 
To further explore the function of CA IV in skin wound healing, we produced and purified 
recombinant CA IV enzyme. CA IV is especially suitable for therapeutic applications as it is an 
extracellular enzyme and has one of the highest enzymatic activity levels of the CAs. In SDS gel 
electrophoresis, a major band was identified at 30 kDa representing a full length recombinant CA 
IV (Supplementary Figure 2). The affinity purified CA IV enzyme had a specific activity of 3000 - 
4000 unit/mg of pure enzyme. 
 
3.7 Wound treatment with CA IV and acetazolamide 
Next, we examined the effects of recombinant CA IV and endogenously expressed CAs on wound 
healing, focusing on the re-epithelialization obtained by keratinocyte migration. Rodents can close 
wounds by two different means: wound contraction or by true re-epithelialization (Davidson et al., 
2013). To alleviate wound contraction and to explore re-epithelialization specifically, a special skin 
excision wound-model was employed, where a round silicone splint is sutured into the skin to 
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firmly attach the underlying dermis and subcutis (Davidson et al., 2013). The wounded animals 
were divided into three groups that received topically applied saline (control), recombinant CA IV 
enzyme, or CA inhibitor (azetazolamide) in Pluronic-127 gels (Blanc-Brude et al., 2002). No 
differences were detected in the size of wounds immediately after wounding or at the size of the 
scab covering the wound at the end of treatment trial (Supplementary Figure 3). The recombinant 
CA IV enhanced the wound re-epithelialization (Figure 5). The epithelial tongues were significantly 
longer in the recombinant CA IV-treated wounds than in the control wounds (P<0.0001) (Figure 5). 
We could not see any difference in the amount of granulation tissue produced in the wounds 
between the three treatment groups (Figure 5). 
 
 
4. Discussion 
 
Skin wound closure is obtained by re-epithelialization, i.e. lateral migration of the keratinocytes. It 
occurs mainly under hypoxia, but the stimuli for it are poorly understood. The present study shows 
that mRNA expression of two members of the CA family, CA IV and IX, are increased during the 
early phase of wound healing, and the cells expressing the CAs form a band-like structure just 
underneath the migrating epidermis in the healing skin wound. Furthermore, we demonstrate that 
exogenously added recombinant Car4 enzyme accelerates wound re-epithelialization during the 
hypoxic phase of wound healing.  
In hypoxic tissues, such as fast growing cancers and wounds, metabolic processes produce high 
amounts of both lactic acid and carbon dioxide. CAs are enzymes that convert carbon dioxide and 
water to bicarbonate and protons (Benej et al., 2014; Pastorekova et al., 1997; Waheed and Sly, 
2014). Because the intracellular pH has to remain stable, all excess acidity is efficiently exported 
from the cells. This, in turn, makes the extracellular environment acidic which provides a favorable 
environment for cancer cell migration and invasion (Pastorekova et al., 2006). CAs have been 
linked to this process by reports showing that the cancer cell invasion can be reduced by CA 
inhibitors whereas the expression of CAs, in turn, facilitates the cancer cell migration and invasion 
(Pastorekova et al., 2006). 
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Of the two CAs that showed enhanced expression during wound healing, CA IX is known to be 
induced by hypoxia. It has a hypoxia-response element (HRE) in its promotor region and is one of 
the known target genes for hypoxia inducible factor-1α (HIF-1α) (Benej et al., 2014; Pastorekova et 
al., 1997). Strikingly, the expression of CA IV was substantially higher than CA IX at mRNA level 
during hypoxia in the skin wound. The expression of CA IV is usually reduced in tumors (Niemela 
et al., 2007), and the present results show that it does not possess a classical HRE in its promoter 
region where HIF-1α could bind. Furthermore, we employed a pure hypoxia driven angiogenesis 
model in retina and could not detect any changes in the expression of Car4 by varying oxygen 
levels. Our results, in essence, rule out the possibility that hypoxia is responsible for the induction 
of Car4 expression.  
The comparative genomics prediction of potential transcription factor binding sites in the promoter 
of primary human CA4 transcript ENST00000300900 revealed some high-scoring candidates that 
may alter the expression of this protein. In particular, there is a cluster of well conserved binding 
sites for KLF4, SP1, and MZF1 which were all near a similarly conserved CTCF binding site. 
CTCF is a well-established actor in chromatin configuration and gene transcription across the 
genome (Vietri Rudan and Hadjur, 2015), as such its presence and proximity gives greater weight to 
the other proximal predictions. MZF1 is involved in myeloid cell differentiation (Hui et al., 1995), 
thus potentially explaining the origin of strong CA4 expression in neutrophils. KLF4, in turn, has 
been shown to be expressed in inflammation (Sevilla et al., 2015) and wound healing (Kaushik et 
al., 2010; Li et al., 2012; Liu et al., 2015; Ou et al., 2015).  
Our RNA-Seq analysis showed low levels of CA4 RNA in normal skin and high levels in 
neutrophils. This implies that the observed elevation of CA4 mRNA and protein in our experiments 
may be due to recruitment of neutrophils to the wound site, which is in line with the fact that 
abundant neutrophil extravasation takes place in skin wounds rapidly after wounding. Interestingly, 
those few neutrophils that persist in the wound are known to make a band-like formation just 
underneath the migrating epidermis (Grguric-Smith et al., 2015). Especially strong production of 
CA IV and IX just beneath the migrating epidermis suggests that these enzymes could generate an 
acidic “micro-environment” within healing wound tissue to aid selectively the keratinocyte 
migration, i.e. closure of the wound. 
Concerning CA IX expression in skin wound, RNA-Seq analysis confirmed expression of CA9 
mRNA in only fibroblasts and skin, with that in fibroblasts being significantly higher. The CA IX 
protein has been shown to be upregulated in tumor fibroblasts undergoing hypoxia (Ishii et al., 
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2005; Santi et al., 2013); while fibroblast-derived HIF-1α  has been shown to be crucial for wound 
healing (Duscher et al., 2015). 
Based on the expression pattern of CA family members, we conclude that it is CAs IV and IX 
which are responsible for maintaining the pH-balance during the skin wound healing. We were able 
to see induction of CA IV and CA IX mRNAs during the early, hypoxic phases of the wound 
healing and both mRNAs returned to the same level as normal skin in seven days. This implies that 
there is rapid induction of these proteins in response to hypoxia (HIF1α-mediated for CA IX) and 
inflammation (CA IV). 
To understand the function of CAs in tissue regeneration in general, we treated skin wounds with 
recombinant human CA IV enzyme and also with a clinically used CAs inhibitor to block the 
endogenously expressed CA activity. We could detect accelerated wound re-epithelialization by 
recombinant CA IV, but the blocking of endogenously expressed CA activity showed no significant 
effect on the wound re-epithelialization. This discrepancy is explained most likely by the fact that 
endogenous CA-accumulation in the skin wound starts at least a few days after the wounding. Thus, 
the CA inhibitor was unlikely to encounter any enhanced CA protein expression during the majority 
of our study period (Days 0 – 5), whereas the exogenously added recombinant CA enzyme provided 
a clear benefit over endogenous enzyme as it was present in the wound immediately after the 
wounding. This is highly relevant for CA4 as our data indicates that its primary source in the wound 
bed is neutrophils, which start to extravasate to the wound within several hours after the injury. 
Future studies are warranted to address whether CAs could be used to stimulate tissue regeneration 
during injury induced hypoxia. CA IV may participate in promoting tissue regeneration by 
generating an acidic “micro-environment” for migrating epidermis to close the wound during 
hypoxic phase of wound healing. 
 
 
5. MATERIALS AND METHODS 
 
5.1 Generation of skin wounds 
For the qPCR and immunohistochemistry analyses, eight-week-old male BALB/c mice (weighing 
23–25 g) were used. Mice were fed with standard laboratory pellets and water ad libitum. All 
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animal experiments were performed in accordance with protocols approved by the National Animal 
Ethics Committee of Finland.  
6-mm diameter, full thickness (including panniculus carnosus muscle) excision wounds were made 
in the dorsal skin under sevoflurane-anesthesia as described previously (Järvinen and Ruoslahti, 
2007). At various time-points the animals were sacrificed and the wounded tissue collected and 
processed for further analyses.  
 
5.2 Quantitative PCR (qPCR) analysis 
Total skin wound RNA from various time-points was converted to cDNA by reverse transcription 
using the High capacity cDNA reverse transcription Kit for RT-qPCR (Applied Biosytems Inc, CA, 
USA). Duplicate qRT-PCR reactions were performed with PowerSYBR SybrGreen reagents 
(Applied Biosytems Inc, CA, USA) on an ABI 7000 Real Time PCR System (Applied Biosytems 
Inc, CA, USA). Details for primers used are listed in Supplementary Table 1. As negative controls, 
no-template and no-reverse transcriptase controls were also included (which were herein negative). 
Data analyses were performed according to Livak and Schmittgen (Livak and Schmittgen, 2001). 
 
5.3 Expression and purification of recombinant human CA IV 
cDNA for the secretory form of human CA IV was cloned in pET-11d, a bacterial expression 
vector, as described previously (Waheed et al., 1997). Briefly, the E. coli strain Rosetta(DE3)pLysS 
was used for enzyme production. The enzyme was purified using a CA-inhibitor affinity column 
(Waheed et al., 1997). Affinity pure enzyme was dialyzed against 20 mM ammonium bicarbonate 
for several changes of the buffer. Endotoxin removal was performed by using a specialized 
endotoxin removal column three times (Hyglos Blue Endotoxin Removal Column, Starnberg, 
Germany). The protein samples were then re-dialyzed with saline, filter-sterilized, and stored at 4 
°C. Recombinant CA IV was analyzed on an Invitrogen NuPAGE 4–12% gradient gel (Life 
Technologies). The enzymatic activity of recombinant CA IV was assayed as described previously 
(Waheed et al., 1997).  
 
15 
 
5.4 Skin wound treatment trial with recombinant CA IV 
For the treatment trial, male littermate BALB/c mice of age 8 weeks were used. Two 6 mm circular, 
full thickness wounds were generated in each animal by biopsy punch. A donut-shaped 12-mm 
silicone splint (Grace Bio-Labs) was placed around the wounds and affixed with glue and sutures in 
order to prevent wound contraction (Davidson et al., 2013). Mice were given plastic collars to 
prevent them from tearing off the splints (Davidson et al., 2013). The operated mice were divided to 
three groups. The first group consisted of mice treated with CA IV; purified CA IV was mixed in 30 
% Pluronic-127 (Sigma-Aldrich) gel as described previously (Blanc-Brude et al., 2002). 50 µl of the 
mixture was added to each wound to fill up the entire wound cavity. The second group received a 
CA inhibitor, acetazolamide (1.0 mM, Orion, Espoo, Finland) in Pluronic-127 gel. The third group 
was used as a control group and was treated with 50 µl of PBS mixed with Pluronic-127 gel. The 
final concentration of Pluronic-127 in each solution was 18 %. Each mouse was photographed after 
the silicone splints had been sutured securely in place and then at sacrifice on day 5.  
 
5.5 RNA-Seq analysis of wound-specific tissues 
RNA-Seq data from human B-cells, CD4-positive cells, CD8-positive cells, monocytes, neutrophils, 
natural killer (NK) cells, monocytes (ArrayExpress accession E-GEOD-60424)(Linsley et al., 
2014), dermal fibroblasts (E-GEOD-72589), undifferentiated and differentiated keratinocytes (E-
MTAB-1717) (Jones et al., 2014), M1 and M2 macrophages (E-GEOD-36952), and skin cells (E-
MTAB-2836) (Uhlen et al., 2015) were retrieved from the Array Express database. Reads for all 
samples were pooled by tissue type and mapped to CA genes in the human genome using the 
Bowtie (Langmead et al., 2009) and Tophat (Trapnell et al., 2009) modules of the Tophat package 
utilizing supercomputer resources provided by CSC – IT Center for Science of the Finnish Ministry 
of Education and Culture. Subsequent matches were then compared to reference CA transcript 
structures from the Ensembl database using the Cuffcompare module of the Cufflinks package 
(Trapnell et al., 2010). Normalized fragments per kilobase of transcript per million mapped reads 
(FPKM) values were generated for each transcript identified in each tissue using the Cuffnorm 
module of the Cufflinks package in order to compare expression values across pooled samples. A 
comparison of expression for each CA across tissue types was calculated using the Cuffmerge and 
Cuffdiff modules of Cufflinks.  Results were visualized using the cummeRbund R library. 
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5.6 Statistical analysis 
Data was presented as mean ± standard deviation. For comparisons of multiple groups, statistical 
analysis was carried out by two-way analysis of variance (ANOVA) complemented by the Bonferroni 
post hoc test for pair wise comparisons between the test groups. P-value < 0.05 was considered 
significant. 
 
5.7 Supplementary Methods 
Extraction of RNA, oxygen induced retinopathy (OIR) model, immunohistochemistry, histology, 
quantitative analysis of histology, promoter analysis of the primary CA4 transcript and GO analysis 
of proteins were performed using standard methods (Jarvinen and Ruoslahti, 2010; May et al., 
2015; Mi et al., 2013; Uusitalo-Jarvinen et al., 2007) and are described in detail in Supplementary 
data set. 
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11. FIGURE LEGENDS 
11.1 Figure 1.  
Figure 1. mRNA expression of CA4 and CAIX during wound healing. 
Skin excision wounds were generated in WT mice as described in the methods. Normal skin and 
skin wound samples were collected from unwounded mice and from mice sacrificed at various 
time-points after wounding. The skin samples were processed for qPCR analysis as described in the 
methods. Results for all enzymatically active CAs are shown as mean ± SD. Animal numbers: 
unwounded: n = 2; Day 2: n = 2; Day 3: n = 2; Day 5: n = 3; Day 7: n = 2; Day 10: n = 2; Day 14: n 
= 2. 
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11.2 Figure 2. 
 
Figure 2. Protein expression of Car4 and Car9 during wound healing. 
Skin excision wounds were generated in WT mice as described in the methods. Normal skin and 
skin wound samples were collected from unwounded mice and from mice sacrificed at various 
time-points after the wounding. The skin samples were processed for IHC analysis and CA IV and 
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CA IX were detected with specific antibodies as described in the supplementary methods. Results at 
all studied time-points are shown. CA IV protein expression started to accumulate in the early 
granulation tissue at day 5 of the healing and positive expression remained in the wound until day 
10, after which the expression disappeared. CA IV protein was expressed mainly by the cells in 
granulation tissue with especially strong expression just beneath migrating epidermis. CA IX 
protein expression, in turn, was already seen in the skin wound at day 2 and remained elevated 
throughout the wound healing process. Animal numbers: All time-points n = 12. 
 
11.3 Figure 3. 
 
Figure 3. Expression of CA4 and CA9 in wound related cells 
RNA-Seq data for multiple immune and wound healing related cells was retrieved from 
experiments housed in the ArrayExpress database and mapped to the genomic locations of all CA 
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genes using Tophat. The reads were then merged using Cuffmerge, and differential expression 
determined using Cuffdiff. Finally, the results were manipulated using the R package cummeRbund 
and visualized in R. Expression abundance measurements are represented on the y-axis as 
normalized fragments per kilobase of transcript per million mapped reads (FPKM) for CA4 (A) and 
CA9 (B). 
 
11.4 Figure 4. 
 
Figure 4. Comparative genomics analysis of CA4 promoter.  
An alignment of 15 mammal sequences corresponding to the promoter of full length human CA4 
transcript ENST00000300900 was analyzed for putative transcription factor binding sites by 
comparative genomics.  The 10 best scoring transcription factors were included in the figure, where 
height indicates the number of species supporting that prediction.  Positive y-axis results indicate a 
TFBS predicted on the sense strand while negative y-axis indicates the anti-sense strand. 
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11.5 Figure 5. 
 
Figure 5. Accelerated re-epithelialization during wound healing in mice treated with 
recombinant Car4 enzyme. 
Mice with full thickness skin excision wounds were treated with either recombinant Car4 enzyme or 
CA inhibitor applied on wound topically immediately after the wounding. Scars were harvested on 
day 5, and the re-epithelialization (A) and cross-sectional area of the granulation tissue (B) of the 
wounds were quantified by examining two microscopic sections from each wound. The results are 
expressed as the average of the two values. There were five animals, each with two wounds, in 
every treatment group. *P < 0.05; ANOVA. The results are expressed as mean ± SD, n = 10. (C) 
Representative sections from wounds treated with recombinant CAIV or CA inhibitor and collected 
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on day 5 after wounding are shown for re-epithelialization. Bars; 600 µm small magnification, 240 
µm high magnification. 
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13. SUPPLEMENTARY FIGURES 
 
13.1 Supplementary Figure 1. 
 
Supplementary Figure 1. Expression of Car4 in oxygen induced retinopathy (OIR) model. 
The effects of hypoxia on Car4 mRNA expression in retina was studied with the OIR model. 
Retinas were harvested at P7, immediately after the exposure to hyperoxia (P12), after hypoxia-
driven pathological angiogenesis has reached its maximum at P17 and when the retinal vasculature 
returns to normal at P28. Retinas were processed for qPCR analysis as described in methods. 
Results for Car4 are shown as mean ± SD. qPCR analysis of gene expression of the Car4 are shown 
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relative to the expression level in the normal retina at P7. Animal numbers: P7: n = 2; P12 OIR: n = 
2; P17 OIR: n = 2; P28 OIR: n = 2. 
 
13.2 Supplementary Figure 2.  
 
Supplementary Figure 2. Production of recombinant Car4 enzyme. 
Gel electrophoretic analysis of recombinant Car4 enzyme. The recombinant protein was expressed 
in E. coli, purified with affinity column, dialyzed and separated on gradient SDS/PAGE gels, and 
detected with Coomassie Blue staining. The major band at 30 kDa represents full length 
recombinant Car4 and minor bands of 60 kDa and 15 kDa represent dimeric and proteolytically 
nicked Car4. 
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13.3 Supplementary Figure 3. 
Supplementary Figure 3. Wound closure in mice treated with recombinant Car4 enzyme. Mice 
with full thickness skin excision wounds were treated with either recombinant Car4 enzyme or CA 
inhibitor applied on wound topically immediately after the wounding. Wounds were harvested on day 
5, and the wound size (A) and closure were assessed from digital photos using ImageJ program and 
expressed as mm
2
. (B) Representative digital pictures of the wounds treated with recombinant CA IV 
or CA inhibitor and collected on day 5 after wounding are shown for wound size and closure.  
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13.4 Supplementary Table 1. Primers used for qPCR.                                                                
All primer pairs have been designed to span exons to amplify only mRNA but not genomic DNA. 
The primers don’t bind to known SNP positions. 
 
gene 
 
primer sequence (5´- 3´) 
Forward/Reverse 
 
product 
size 
 
CA I 
F: TTGATGACAGTAGCAACC 
R: CCAGTGAACTAAGTGAAG 
161 
 
CA II 
F: CAAGCACAACGGACCAGA 
R: ATGAGCAGAGGCTGTAGG 
122 
 
CA III 
F: GCTCTGCTAAGACCATCC 
R: ATTGGCGAAGTCGGTAGG 
160 
 
CA IV 
F: CTCCTTCTTGCTCTGCTG 
R: GACTGCTGATTCTCCTTA 
145 
 
CA Vb 
F: AATGGCTTGGCTGTGATAGG 
R: GGCGTAGTGAGAGACCCAGA 
104 
 
CA VI 
F: AAGATTGACGAGTATGCC 
R: TAGGTGTAATAGTGGTGG 
145 
 
CA VII 
F: CAATGACAGTGATGACAGAA 
R: TCCAGTGAACCAGATGTAG 
160 
 
CAIX 
F: CTGAAGACAGGATGGAGAAG 
R: GCAGAGTGCGGCAGAATG 
221 
 
CA XII 
F: CCTATGTTGGTCCTGCTG 
R: CGTTGTAACCTTGGAACTG 
143 
 
CA XIII 
F: AATACGACTCCTCACTCC 
R: TGCCGCAACCTGTAGTTC 
116 
 
CA XV 
F: AGCACAGCCTGGATGAGA 
R: CAGACACAATGGCAGAGA 
170 
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13.5 Supplementary Table 2.  Results of mapping RNA-Seq to CA gene 
annotations 
CA transcripts were identified whose intron/exon boundaries exactly match (=) RNA-Seq data for 
various tissues.  Expression of those tissues are given in FPKM. 
Tissue 
ref 
gene 
id ref_id 
class 
code 
FPKM 
norm FPKM cov len 
ref 
match 
len 
b-cells CA14 ENST00000582010 = 87122.9 91022.1 762.22 1176 1514 
b-cells CA11 ENST00000084798 = 3448.2 3653.094 55.304 1821 1844 
b-cells CA13 ENST00000321764 = 2277.11 2742.349 26.322 3501 3815 
b-cells CA3 ENST00000522207 = 251.976 159.8924 1.7738 451 645 
b-cells CA2 ENST00000285379 = 640.757 640.8174 9.9529 1494 1717 
b-cells CA5B ENST00000474624 = 1546.2 1198.678 16.976 540 565 
b-cells CA5B ENST00000478923 = 3958.35 2490.461 35.27 458 578 
monocytes-
healthy CA11 ENST00000599267 = 1003.44 298.9805 3.8704 378 381 
monocytes-
healthy CA11 ENST00000594088 = 3271.37 795.5951 10.299 324 275 
monocytes-
healthy CA13 ENST00000321764 = 3883.35 2590.069 20.093 3662 3815 
monocytes-
healthy CA2 ENST00000285379 = 2887.26 1599.104 22.549 1443 1717 
nk CA11 ENST00000084798 = 2528.87 1892.243 25.673 1777 1844 
nk CA8 ENST00000317995 = 354.884 273.4874 3.8527 3265 3812 
nk CA3 ENST00000285381 = 371.297 267.6843 3.8554 1660 1753 
nk CA5B ENST00000478923 = 9493.39 5117.402 66.587 589 578 
macrophage-m2 CA12 ENST00000344366 = 2151.21 9164.784 4.5811 3734 2744 
macrophage-m2 CA11 ENST00000084798 = 37616.3 168812 92.635 1575 1844 
macrophage-m2 CA2 ENST00000285379 = 65333.7 283239.7 154.21 1443 1717 
macrophage-m2 CA5B ENST00000454127 = 2380.91 12330.23 6.2201 5340 2205 
keratinocytes-
undif CA12 ENST00000178638 = 4344.74 6230.474 139.9 4083 6413 
keratinocytes-
undif CA11 ENST00000084798 = 626.232 859.8755 20.392 1780 1844 
keratinocytes-
undif CA2 ENST00000285379 = 1468.46 1948.369 50.135 1476 1717 
skin CA6 ENST00000377443 = 524.686 1888.604 16.219 1233 1319 
skin CA14 ENST00000369111 = 789.664 3458.73 30.645 2276 2403 
skin CA12 ENST00000344366 = 12078.4 37267.41 336.3 4032 2744 
skin CA12 ENST00000178638 = 26995.9 140397.4 1266.9 4065 6413 
skin CA4 ENST00000300900 = 107.319 359.4333 3.2884 860 1154 
skin CA11 ENST00000084798 = 2600.57 10466.45 88.309 1710 1844 
skin CA8 ENST00000317995 = 110.369 495.9338 4.4609 3532 3812 
skin CA13 ENST00000321764 = 1111.41 5058.904 45.134 3542 3815 
skin CA1 ENST00000523022 = 182.5 644.5951 4.7867 1055 1208 
skin CA3 ENST00000285381 = 940.788 4074.264 35.885 1745 1753 
skin CA2 ENST00000285379 = 17679.2 73994.29 688.66 1561 1717 
skin CA9 ENST00000378357 = 2254.86 8751.696 79.151 1507 1618 
macrophage-m1 CA12 ENST00000344366 = 23522.3 59399.86 79.78 3742 2744 
macrophage-m1 CA12 ENST00000178638 = 27296.2 65408.2 87.849 3775 6413 
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macrophage-m1 CA11 ENST00000084798 = 17346.9 39907.33 54.74 1730 1844 
macrophage-m1 CA2 ENST00000285379 = 119454 264718.7 375.86 1433 1717 
macrophage-m1 CA5B ENST00000498004 = 3350.94 6219.821 8.2757 717 488 
neutrophils CA4 ENST00000300900 = 19051 14791.68 173.57 1152 1154 
neutrophils CA2 ENST00000285379 = 996.678 765.6827 9.7061 1463 1717 
cd4 CA11 ENST00000084798 = 2824.52 3659.525 46.077 1759 1844 
cd4 CA5B ENST00000478923 = 7897.18 7214.55 83.642 550 578 
dermal-fibroblasts CA12 ENST00000344366 = 132367 70010.04 933.04 6372 2744 
dermal-fibroblasts CA11 ENST00000084798 = 3075.12 1513.818 20.175 1829 1844 
dermal-fibroblasts CA13 ENST00000321764 = 2867.36 1585.355 21.128 3771 3815 
dermal-fibroblasts CA9 ENST00000378357 = 81208.8 38762.42 516.59 1618 1618 
keratinocytes-dif CA14 ENST00000582010 = 50512.5 78051.22 890.39 1445 1514 
keratinocytes-dif CA12 ENST00000178638 = 6963.37 9150.187 169.69 4126 6413 
keratinocytes-dif CA11 ENST00000084798 = 727.176 952.2422 18.887 1835 1844 
keratinocytes-dif CA2 ENST00000285379 = 2115.47 2529.393 52.97 1468 1717 
cd8 CA14 ENST00000582010 = 115928 93747.34 656.77 1165 1514 
cd8 CA11 ENST00000084798 = 3791.96 3127.982 39.633 1799 1844 
cd8 CA2 ENST00000285379 = 651.919 493.62 6.5076 1307 1717 
cd8 CA5B ENST00000318636 = 63903 57353.93 415.43 6775 6835 
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13.6 Supplementary Table 3. Gene ontology enrichment analysis of 1063 genes 
with a correlation of expression with CA4 of 0.5 or greater in skin. 
Correlation of expression data was retrieved from the Medisapiens database of microarray 
experiments, and GO enrichment analysis was performed using  
GO biological process ref actual expected 
fold 
change P-value 
regulation of natural killer cell chemotaxis (GO:2000501) 8 6 0.38 15.79 2.27E-002 
neutrophil chemotaxis (GO:0030593) 64 16 3.03 5.28 1.01E-003 
granulocyte chemotaxis (GO:0071621) 68 17 3.22 5.28 4.13E-004 
neutrophil migration (GO:1990266) 67 16 3.17 5.05 1.84E-003 
granulocyte migration (GO:0097530) 72 17 3.41 4.99 9.17E-004 
cellular defense response (GO:0006968) 61 14 2.89 4.84 1.62E-002 
positive regulation of leukocyte chemotaxis (GO:0002690) 78 17 3.69 4.61 2.75E-003 
myeloid leukocyte migration (GO:0097529) 95 20 4.5 4.44 4.58E-004 
leukocyte chemotaxis (GO:0030595) 115 24 5.44 4.41 2.66E-005 
regulation of leukocyte chemotaxis (GO:0002688) 92 19 4.35 4.37 1.30E-003 
chemokine-mediated signaling pathway (GO:0070098) 73 15 3.45 4.35 2.67E-002 
positive regulation of chemotaxis (GO:0050921) 114 22 5.39 4.08 4.53E-004 
positive regulation of behavior (GO:0048520) 135 25 6.39 3.91 1.28E-004 
positive regulation of leukocyte migration (GO:0002687) 103 19 4.87 3.90 6.86E-003 
regulation of chemotaxis (GO:0050920) 152 27 7.19 3.76 8.12E-005 
cell chemotaxis (GO:0060326) 164 28 7.76 3.61 9.97E-005 
regulation of behavior (GO:0050795) 208 34 9.84 3.46 8.45E-006 
cellular response to interferon-gamma (GO:0071346) 127 20 6.01 3.33 3.75E-002 
regulation of leukocyte migration (GO:0002685) 139 21 6.58 3.19 4.10E-002 
leukocyte migration (GO:0050900) 256 38 12.11 3.14 1.23E-005 
regulation of vasculature development (GO:1901342) 211 29 9.99 2.90 4.82E-003 
regulation of angiogenesis (GO:0045765) 195 26 9.23 2.82 3.07E-002 
regulation of endocytosis (GO:0030100) 195 26 9.23 2.82 3.07E-002 
inflammatory response (GO:0006954) 432 55 20.44 2.69 8.24E-007 
regulation of peptide transport (GO:0090087) 264 33 12.49 2.64 6.60E-003 
cellular calcium ion homeostasis (GO:0006874) 284 34 13.44 2.53 1.15E-002 
calcium ion homeostasis (GO:0055074) 298 35 14.1 2.48 1.24E-002 
cellular divalent inorganic cation homeostasis (GO:0072503) 298 35 14.1 2.48 1.24E-002 
divalent inorganic cation homeostasis (GO:0072507) 320 37 15.14 2.44 9.00E-003 
regulation of response to wounding (GO:1903034) 383 43 18.13 2.37 2.70E-003 
positive regulation of response to external stimulus 
(GO:0032103) 383 43 18.13 2.37 2.70E-003 
ion homeostasis (GO:0050801) 559 62 26.45 2.34 1.11E-005 
metal ion homeostasis (GO:0055065) 470 51 22.24 2.29 6.29E-004 
cellular metal ion homeostasis (GO:0006875) 398 42 18.83 2.23 1.72E-002 
synaptic transmission (GO:0007268) 560 59 26.5 2.23 1.66E-004 
inorganic ion homeostasis (GO:0098771) 533 56 25.22 2.22 4.17E-004 
cation homeostasis (GO:0055080) 519 54 24.56 2.20 9.78E-004 
cellular cation homeostasis (GO:0030003) 435 45 20.59 2.19 1.26E-002 
cellular ion homeostasis (GO:0006873) 445 46 21.06 2.18 9.90E-003 
cellular chemical homeostasis (GO:0055082) 526 51 24.89 2.05 1.63E-002 
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14. SUPPLEMENTARY METHODS 
 
 
14.1 Extraction of RNA 
Skin wound samples and retinas were collected, snap frozen in liquid nitrogen, stored at −80 °C, 
and preserved in Ambion RNALater ICE Frozen Tissue Transition Solution (Life Technologies). 
The mRNA was then extracted using Invitrogen Trizol Reagent (Life Technologies) as described 
previously, with bead homogenization performed via Precellys’ 2 ml tubes and Precellys®24 
(Bertin Technologies, Villeurbanne, France) homogenizer at 4 °C (May et al., 2015). After the 
addition of chloroform and centrifugation, the aqueous phase was transferred to RNeasy columns 
(Qiagen, Hilden, Germany) and mRNA purification continued according to the manufacturer’s 
instructions. The concentration and quality of RNA was determined by Nanodrop A260 
measurement (May et al., 2015). 
 
14.2 Immunohistochemistry (IHC) 
Hematoxylin/eosin (HE) and IHC stainings were performed on 6 μm thick paraffin sections. The 
following primary antibodies were used for IHC: rabbit anti-mouse CA IV (1:100) and rabbit anti-
mouse CA IX (1:300) (Brion et al., 1997; Gut et al., 2002). For the control stainings, the primary 
anti-CA sera were replaced with normal rabbit serum (NRS). The immunostaining was performed 
as described previously in detail using the Vectastain Elite ABC Reagent kit (Vector Laboratories) 
with 3,3'-Diaminobenzidine tetrahydrochloride (DAB) Substrate Kit (Invitrogen). Finally, the 
sections were examined and photographed with a Zeiss Axioskop 40 microscope (Carl Zeiss, 
Göttingen, Germany). 
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14.3 Histology 
Wound tissue was harvested at five days (n=5 per group) after wounding. Mice were euthanized 
and perfused by intra-cardial injection of 4 % paraformaldehyde (PFA). Excision of a rectangular 
section of skin containing all wounds, as well as underlying skeletal muscle, was performed to 
ensure the uninterrupted wound architecture. The “whole-mounted” sections were immobilized on 
filter paper, immersed in 4% PFA for additional O/N fixation, and washed with physiological 
saline. After O/N fixation, the wounds were bisected, dehydrated, and embedded in paraffin. 
Longitudinal sections (6 μm) from the middle of the wound were stained with HE. 
 
14.4 Morphological assessment of wound closure 
After the surgery and during the sacrifice, the wound were photographed digitally. Two 2 x 2 cm 
cardboard squares were placed on both sides of the animal to adjust the digital pictures taken from 
various distance in relation to wounds and the total area of wound was measured and analyzed from 
digital photographs using ImageJ software by manually drawing the edges of each individual 
wound. 
 
14.5 Quantitative analysis of histology 
Two HE-stained sections from the middle of each wound were quantitatively evaluated, and the 
average of the two values was used in the analysis. The length of epithelial tongues (a measure of 
re-epithelialization) was measured as described by Chen et al. (Chen et al., 2015) and the size of 
granulation tissue was determined. Image analysis and quantification of histological parameters, 
were performed using Spectrum digital pathology system (Aperio Technologies) using the Aperio 
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ScanScope CS and XT systems (Aperio Technologies) as described previously elsewhere (Järvinen 
and Ruoslahti, 2010). Slides were viewed and analyzed with the ImageScope viewer. The areas of 
interests were recorded manually for each wound. 
 
14.6 Oxygen-induced retinopathy (OIR) model 
The experiments utilizing the OIR model were carried out as described in detail previously (Smith 
et al., 1994; Uusitalo-Jarvinen et al., 2007). Briefly, neonatal C57BL/6 mice at P7 and their nursing 
mother were exposed to 75% oxygen for 5 days in a custom-made oxygen chamber (Smith et al., 
1994; Uusitalo-Jarvinen et al., 2007). At P12, the mice were returned to normal room air. As 
postnatal weight gain has been shown to affect outcome in the OIR model, the pups were weight-
matched (Stahl et al., 2010). All OIR experiments were performed according to the ARVO 
statement for the use of animals in ophthalmic and vision research. 
 
14.7 Promoter analysis of the primary CA4 transcript 
A computational comparative genomics analysis was performed on the promoter region of the human 
CA4 gene (Ensembl: ENSG00000167434), defined as the region 900 base pairs (bp) upstream and 
100 bp downsteam of the transcription start site (TSS). Of the four protein coding transcripts for this 
gene identified in the Ensembl database, human transcript ENST00000300900 (CA4-001) was 
chosen based on our analysis of RNA-Seq data. This transcript encodes a full-length 312 amino acid 
(aa) protein while the others produce significantly shorter (38-184 aa) polypeptides. An alignment of 
the corresponding promoter nucleotide sequences of 15 mammalian species (including human) was 
retrieved from the Ensembl database. Experimentally determined binding sites for transcription 
factors were retrieved from the Jaspar database from which dinucleotide weight matrices were 
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produced for log likelihood scoring of potential transcription factor binding sites (TFBSs). After 
scoring all possible positions in the nucleotide sequences of all species, locations where high scoring 
potential TFBSs were observed in multiple species were identified. 
 
14.8 GO analysis of proteins 
The Medisapiens database (Kilpinen et al., 2008) (http://ist.medisapiens.com/) houses data from a 
large number of microarray expression studies. For skin tissue there were at least 135 microarray 
experiment samples for all genes present on a human genome U133 chip. We extracted all 
expression correlation values for CA4 with all other genes. The subset of these genes that had a 
positive correlation of expression of 0.50 or greater totaled 1,063, which were then used to perform 
a biological processes gene ontology enrichment analysis using the (http://geneontology.org) 
webserver (Ashburner et al., 2000; Gene Ontology Consortium, 2015).  The gene ontology terms 
which were enriched among our subset of CA4 positively correlated genes at 2-fold or greater were 
then analyzed for biological significance. 
 
  
38 
 
15. REFERENCES FOR SUPPLEMENTARY METHODS 
 
(1) May U, Prince S, Vähätupa M, Laitinen AM, Nieminen K, Uusitalo-Järvinen H, et al. 
Resistance of R-Ras knockout mice to skin tumour induction. Sci Rep 2015 Jul 2;5:11663. 
(2) Brion LP, Cammer W, Satlin LM, Suarez C, Zavilowitz BJ, Schuster VL. Expression of 
carbonic anhydrase IV in carbonic anhydrase II-deficient mice. Am J Physiol 1997 Aug;273(2 Pt 
2):F234-45. 
(3) Gut MO, Parkkila S, Vernerova Z, Rohde E, Zavada J, Hocker M, et al. Gastric hyperplasia in 
mice with targeted disruption of the carbonic anhydrase gene Car9. Gastroenterology 2002 
Dec;123(6):1889-1903. 
(4) Chen L, Mirza R, Kwon Y, DiPietro LA, Koh TJ. The murine excisional wound model: 
Contraction revisited. Wound Repair Regen 2015 Nov 12;23(6):874-877. 
(5) Järvinen TA, Ruoslahti E. Target-seeking antifibrotic compound enhances wound healing and 
suppresses scar formation in mice. Proc Natl Acad Sci U S A 2010 Dec 14;107(50):21671-21676. 
(6) Smith LE, Wesolowski E, McLellan A, Kostyk SK, D'Amato R, Sullivan R, et al. Oxygen-
induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 1994 Jan;35(1):101-111. 
(7) Uusitalo-Jarvinen H, Kurokawa T, Mueller BM, Andrade-Gordon P, Friedlander M, Ruf W. 
Role of protease activated receptor 1 and 2 signaling in hypoxia-induced angiogenesis. Arterioscler 
Thromb Vasc Biol 2007 Jun;27(6):1456-1462. 
(8) Stahl A, Chen J, Sapieha P, Seaward MR, Krah NM, Dennison RJ, et al. Postnatal weight gain 
modifies severity and functional outcome of oxygen-induced proliferative retinopathy. Am J Pathol 
2010 Dec;177(6):2715-2723. 
(9) Kilpinen S, Autio R, Ojala K, Iljin K, Bucher E, Sara H, et al. Systematic bioinformatic analysis 
of expression levels of 17,330 human genes across 9,783 samples from 175 types of healthy and 
pathological tissues. Genome Biol 2008;9(9):R139-2008-9-9-r139. Epub 2008 Sep 19. 
(10) Gene Ontology Consortium. Gene Ontology Consortium: going forward. Nucleic Acids Res 
2015 Jan;43(Database issue):D1049-56. 
(11) Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene ontology: tool 
for the unification of biology. The Gene Ontology Consortium. Nat Genet 2000 May;25(1):25-29. 
  
 
 
 
